Publications

Spotlight Publication

Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)

European Society for Medical Oncology (ESMO) GI

Jun 26
- Jun 29, 2024
Neoadjuvant botensilimab (BOT) plus balstilimab (BAL) in resectable mismatch repair proficient and deficient colorectal cancer
Kasi, et. al.

Filter by

Botensilimab (Fc-Enhanced CTLA-4 Antagonist)

American Association for Cancer Research (AACR)

Apr 9
- Apr 14, 2021
Characterization of The Pharmacodynamic Activity of AGEN1181, an Fc-enhanced CTLA-4 Antibody, Alone and in Combination With the PD-1 Antibody Balstilimab.
Shapiro, et al.
Botensilimab (Fc-Enhanced CTLA-4 Antagonist)

American Association for Cancer Research (AACR)

Apr 9
- Apr 14, 2021
Fc-enhanced anti-CTLA-4 Antibody, AGEN1181: New Mechanistic Insights for Potent Antitumor Immunity and Combination Potential in Treatment-resistant Solid Tumors.
Tanne, et al.
Botensilimab (Fc-Enhanced CTLA-4 Antagonist)

Society for Immunotherapy of Cancer (SITC)

Nov 10
- Nov 14, 2021
AGEN1181, an Fc-enhanced anti-CTLA-4 antibody, alone and in combination with balstilimab (anti-PD-1) in patients with advanced solid tumors: Initial phase I results.
El-Khoueiry, et al.
Balstilimab (PD-1 Antagonist)

Society for Immunotherapy of Cancer (SITC)

Nov 9
- Nov 12, 2017
AGEN2034, a Novel anti-PD-1 Antibody that Combines Effectively With CTLA-4 Pathway Blockade to Enhance T Cell Activity.
Chand, et al.
Balstilimab (PD-1 Antagonist)

American Association for Cancer Research (AACR)

Apr 14
- Apr 18, 2018
Evaluation of Peripheral T Cell Subset Proliferation as a Pharmacodynamic Assay to Guide the Development of Anti-CTLA-4 and PD-1 Antibody Combinations in Patients With Solid Tumors.
de Souza, et al.
Balstilimab (PD-1 Antagonist)

American Society of Clinical Oncology (ASCO)

Jun 1
- Jun 5, 2018
Phase One Open-Label, Ascending Dose Trial of AGEN2034, an Anti-PD-1 Monoclonal Antibody, in Advanced Solid Malignancies: Results of Dose Escalation.
Moore, et al.
Balstilimab (PD-1 Antagonist)

European Society for Medical Oncology (ESMO)

Oct 19
- Oct 23, 2018
Phase 1/2 Study of CTLA-4 Inhibitor AGEN1884 + PD-1 Inhibitor AGEN2034 in Patients With Advanced/Refractory Solid Tumors, With Expansion Into Second-Line Cervical Cancer and Solid Tumors.
Coward, et al.
Balstilimab (PD-1 Antagonist)

European Society for Medical Oncology (ESMO)

Oct 19
- Oct 23, 2018
Phase 1/2, Open-Label, Multiple Ascending Dose Trial of AGEN2034, an Anti–PD-1 Monoclonal Antibody, in Advanced Solid Malignancies: Results of Dose Escalation in Advanced Cancer and Expansion Cohorts in Subjects With Relapsed/Refractory Cervical Cancer.
Drescher, et al.
Balstilimab (PD-1 Antagonist)

Society for Immunotherapy of Cancer (SITC)

Nov 6
- Nov 10, 2019
Single-agent Activity of a Novel PD-1 Inhibitor, AGEN2034, in Recurrent Ovarian Cancer.
O’Malley, et al.
Balstilimab (PD-1 Antagonist)

European Society for Medical Oncology (ESMO) Virtual

Sep 19
- Sep 21, 2020
Balstilimab (anti-PD-1) Alone and in Combination with Zalifrelimab (anti-CTLA-4)for Recurrent/Metastatic (R/M) Cervical Cancer (CC) Preliminary Results of Two Independent Ph2 Trials .
O’Malley, et al.
Balstilimab (PD-1 Antagonist)

Oncogene

Jan 26, 2021
Is PD-L1 a consistent biomarker for anti-PD-1 therapy? The model of balstilimab in a virally-driven tumor.
Grossman, et al.
Balstilimab (PD-1 Antagonist)

SGO 2021 Virtual Annual Meetings on Women’s Cancer Abstracts

Mar 19
- Mar 22, 2021
RaPiDS (GOG-3028): A Randomized Phase II Studyof Balstilimab (AGEN2034) as Monotherapy or in Combination with Zalifrelimab (AGEN1884) in Second-Line Cervical Cancer.
O’Malley, et al.